Results 121 to 130 of about 822 (142)
Some of the next articles are maybe not open access.
Drugs, 2021
Ibrexafungerp (BREXAFEMME®) is an orally active triterpenoid antifungal drug being developed by SCYNEXIS, Inc. for the treatment of fungal infections. The inhibition of β-1,3-D glucan synthetase by ibrexafungerp compromises the integrity of fungal cell walls.
openaire +2 more sources
Ibrexafungerp (BREXAFEMME®) is an orally active triterpenoid antifungal drug being developed by SCYNEXIS, Inc. for the treatment of fungal infections. The inhibition of β-1,3-D glucan synthetase by ibrexafungerp compromises the integrity of fungal cell walls.
openaire +2 more sources
Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor
Bioorganic and Medicinal Chemistry Letters, 2021We previously reported medicinal chemistry efforts that identified MK-5204, an orally efficacious β-1,3-glucan synthesis inhibitor derived from the natural product enfumafungin. Further extensive optimization of the C2 triazole substituent identified 4-pyridyl as the preferred replacement for the carboxamide of MK-5204, leading to improvements in ...
James Apgar +2 more
exaly +3 more sources
Ibrexafungerp for the treatment of vulvovaginal candidiasis
Drugs of Today, 2022Worldwide, effective management of vulvovaginal candidiasis (VVC) continues to serve as a major therapeutic goal with numerous unmet drug treatment challenges. After 3 decades of azole drug dominance, with few recent new antifungal agents and little progress in VVC management, the first-in-class oral triterpenoid glucan synthase inhibitor agent ...
openaire +2 more sources
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyAbstractManagement of invasive fungal infections is challenging with growing antifungal resistance. Broad antifungal use has resulted in greater intrinsic and acquired resistance among Candida spp. It is important for clinicians to recognize the relationship between host susceptibility, site of infection, Candida resistance profiles, specific drug ...
Benjamin A. August +1 more
openaire +2 more sources
Journal De Mycologie Medicale
Vulvovaginal candidiasis (VVC) is a prevalent fungal infection affecting millions of women globally, primarily caused by Candida species, most notably Candida albicans. Ibrexafungerp emerges as a promising candidate in the treatment arsenal against VVC, presenting a novel approach to combating this prevalent fungal infection.A systematic literature ...
Dinesh Sangarran Ramachandram +2 more
exaly +3 more sources
Vulvovaginal candidiasis (VVC) is a prevalent fungal infection affecting millions of women globally, primarily caused by Candida species, most notably Candida albicans. Ibrexafungerp emerges as a promising candidate in the treatment arsenal against VVC, presenting a novel approach to combating this prevalent fungal infection.A systematic literature ...
Dinesh Sangarran Ramachandram +2 more
exaly +3 more sources
Obstetrics & Gynecology, 2019
INTRODUCTION: The treatment of fungal infections, like Vulvovaginal Candidiasis (VVC), during pregnancy is difficult due to the teratogenicity associated with existing anti-fungal treatment options. VVC, also known as yeast infection, is especially common during pregnancy. Fluconazole, the oral standard of care,
Christina Carruthers +5 more
openaire +1 more source
INTRODUCTION: The treatment of fungal infections, like Vulvovaginal Candidiasis (VVC), during pregnancy is difficult due to the teratogenicity associated with existing anti-fungal treatment options. VVC, also known as yeast infection, is especially common during pregnancy. Fluconazole, the oral standard of care,
Christina Carruthers +5 more
openaire +1 more source
Antimicrobial Agents and Chemotherapy
ABSTRACT Invasive candidiasis is a major hospital-acquired infection. Usually, echinocandins are considered first-line treatment. However, resistant phenotypes have emerged. Ibrexafungerp (IBX) is a new antifungal substance with potent anti- Candida activity.
Alexander Maximilian Aldejohann +5 more
openaire +2 more sources
ABSTRACT Invasive candidiasis is a major hospital-acquired infection. Usually, echinocandins are considered first-line treatment. However, resistant phenotypes have emerged. Ibrexafungerp (IBX) is a new antifungal substance with potent anti- Candida activity.
Alexander Maximilian Aldejohann +5 more
openaire +2 more sources
Ibrexafungerp to treat acute vulvovaginal candidiasis
Nature Reviews Urology, 2021openaire +2 more sources